EGFR inhibitors, including monoclonal antibodies (e.g., cetuximab and panitumumab) and tyrosine kinase inhibitors (TKIs; e.g., gefitinib and erlotinib), have been evaluated in clinical trials for the treatment of advanced cSCC but have shown only partial clinical benefit.3 The gene discussed is EGFR; the disease is skin squamous cell carcinoma.